Abstract: The present invention relates to a pharmaceutical composition comprising or consisting of a combination of (a) two or more peptides, each peptide consisting of or comprising 17 to 23 amino acids, wherein the amino acids in positions 1 to 23, counted from the N-terminus, are as follows (1) G, S or lacking; (2) C or lacking; (3) K or R; (4) K or R; (5) Y, W or F; (6) K or R; (7) K or R; (8) F, W or L; (9) K or R; (10) K or L or lacking; (11) W, L or F; (12) K or R; (13) F, Y or C; (14) K or R; (15) G or Q; (16) K or R; (17) F, L or W; (18) F or W; (19) F, L or W; (20) W or F; (21) C or lacking; (22) F or G or lacking; (23) G or lacking; or (b) one or more peptides, each peptide consisting of or comprising 17 to 23 amino acids, wherein the amino acids in positions 1 to 23, counted from the N-terminus, are as follows (1) G, S or lacking; (2) C or lacking; (3) K or R; (4) K or R; (5) Y, W or F; (6) K or R; (7) K or R; (8) F, W or L; (9) K or R; (10) K or L or lacking; (11) W, L or F; (12) K or R; (13) F, Y or C; (

Abstract: The present invention relates to a pharmaceutical composition comprising or consisting of a combination of (a) two or more peptides, each peptide consisting of or comprising 17 to 23 amino acids, wherein the amino acids in positions 1 to 23, counted from the N-terminus, are as follows (1) G, S or lacking; (2) C or lacking; (3) K or R; (4) K or R; (5) Y, W or F; (6) K or R; (7) K or R; (8) F, W or L; (9) K or R; (10) K or L or lacking; (11) W, L or F; (12) K or R; (13) F, Y or C; (14) K or R; (15) G or Q; (16) K or R; (17) F, L or W; (18) F or W; (19) F, L or W; (20) W or F; (21) C or lacking; (22) F or G or lacking; (23) G or lacking; or (b) one or more peptides, each peptide consisting of or comprising 17 to 23 amino acids, wherein the amino acids in positions 1 to 23, counted from the N-terminus, are as follows (1) G, S or lacking; (2) C or lacking; (3) K or R; (4) K or R; (5) Y, W or F; (6) K or R; (7) K or R; (8) F, W or L; (9) K or R; (10) K or L or lacking; (11) W, L or F; (12) K or R; (13) F, Y or C; (

Abstract: The present invention relates to a method of preventing or treating hemorrhagic shock (HS), or ameliorating symptoms associated with HS in an individual, by administering an effective amount of a linear, non-cyclic peptide comprising 17 to 21 amino acids, wherein the amino acids in positions (1) to (21) of the peptide, counted from the N-terminus, are as follows: (1) G, S or lacking; (2) C or lacking; (3) K or R; (4) K or R; (5) Y or F; (6) K or R; (7) K or R; (8) F, W or L; (9) K, R or lacking; (10) W, L or F; (11) K or R; (12) F, Y or C; (13) K or R; (14) G or Q; (15) K or R; (16) F, L or W; (17) F or W; (18) F, L or W; (19) W or F; (20) C or lacking; (21) G or lacking, wherein when position (9) is lacking, positions (1) and (21) cannot be lacking.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one Toll-like receptor (TLR)-activating amphiphilic lipid and at least one hemoglobin-derived peptide and optionally a pharmaceutically acceptable carrier. The present invention also relates to the pharmaceutical composition according to the invention for use in preventing and/or treating tumours, preventing and/or treating infections, preventing and/or treating allergies, preventing and/or treating age-related immune imbalances, stimulating the innate and adaptive immune system and/or alleviating the adverse side effects of irradiation. Moreover, the present invention also relates to a hemoglobin-derived peptide as well as its use in treating a bacterial infection.

Abstract: The present invention relates to a peptide of linear, non-cyclic structure consisting of or comprising 17 to 23 amino acids, wherein the amino acids in positions 1 to 23, counted from the N-terminus, are as follows (1) G, S or lacking; (2) C or lacking; (3) K or R; (4) K or R; (5) Y, W or F; (6) K or R; (7) K or R; (8) F, W or L; (9) K or R; (10) K or L or lacking; (11) W, L or F; (12) K or R; (13) F, Y or C; (14) K or R; (15) G or Q; (16) K or R; (17) F, L or W; (18) F or W; (19) F, L or W; (20) W or F; (21) C or lacking; (22) F or G or lacking (23) G or lacking. Further, the invention relates to a nucleic acid molecule encoding the peptide of the invention, an expression vector comprising the nucleic acid molecule of the invention, a host cell which may be grown in cell culture comprising the vector of the invention, and a method of producing the peptide of the invention comprising culturing the host cell of the invention and collecting the peptide produced.

Abstract: The present invention relates to families of polypeptides and lipopolypeptides that have antimicrobial and endotoxin-neutralizing activities. These molecules show a broad spectrum of activity against various pathogens (including bacteria, viruses, fungi etc.) These compounds can be used alone or in combination therapy with conventional antibiotics or antiendotoxic agents. In addition, the present invention discloses processes for making and using of the compounds.

Abstract: The present invention relates to a peptide of linear, non-cyclic structure consisting of or comprising 17 to 23 amino acids, wherein the amino acids in positions 1 to 23, counted from the N-terminus, are as follows (1) G, S or lacking; (2) C or lacking; (3) K or R; (4) K or R; (5) Y, W or F; (6) K or R; (7) K or R; (8) F, W or L; (9) K or R; (10) K or L or lacking; (11) W, L or F; (12) K or R; (13) F, Y or C; (14) K or R; (15) G or Q; (16) K or R; (17) F, L or W; (18) F or W; (19) F, L or W; (20) W or F; (21) C or lacking; (22) F or G or lacking (23) G or lacking. Further, the invention relates to a nucleic acid molecule encoding the peptide of the invention, an expression vector comprising the nucleic acid molecule of the invention, a host cell which may be grown in cell culture comprising the vector of the invention, and a method of producing the peptide of the invention comprising culturing the host cell of the invention and collecting the peptide produced.

Abstract: The present invention relates to peptides with antimicrobial or endotoxin-neutralizing activity having the general formula (Xaa1)M-(Xaa2)0-Xaa3-(Xaa4)P-(Xaa5)Q-(Xaa6)M-(Xaa7)R-(Xaa8)S.

Abstract: In order to reduce corrosion damage in the marginal edge region of a label, as can occur in particular in the case of metallized battery labels in an environment with high atmospheric humidity, it is proposed that, at or close to at least one portion of the peripheral edge (35) of the film layer (23) defining the label contour, the marginal edge (37) of a metallization layer (31) provided between a transparent plastic film layer (23) and a further covering layer (25) be sealed off by a sealing strip (41).

Abstract: A method of operating a printer in which, after positioning of a paper web for printing and the printing of the web, the last printed sheet is removed and the leading edge of the web is retracted in a park position. The retraction of the leading edge of the web from this proper printing position until it passes a sensor is detected and this difference in displacement of the drive is stored for correction of advance of the same web from the parking position subsequently.

Abstract: A printer has a drum with at least one slot for receiving sheet-like record carriers. The slot extends into the circumference of the drum and is dimensioned to receive clamping means for holding the record carrier with a clamping fit. The control of the clamping means is effected, for example, by means of disks which are secured adjacent the end faces of the drum and whose circumference is also engaged by the clamping means. The disks are provided at their outer side with a first stopper element, which resiliently co-operates with a second stopper element secured to the housing of the device in such a manner that upon rotation of the drum in the printing direction of rotation one stopper element slips over the other and upon rotation of the drum in opposite direction prevent the rotation of the disk. Thus, the clamping means are passed out of the slot.

Abstract: An electromagnetic drive for a recording pin of a matrix printer, comprising a cylindrical armature which is displaceable by means of an excitation coil and in which a clamping sleeve is provided which comprises an indentation which encloses the recording pin in a clamping manner and whose length governs the position of the recording pin.

Abstract: In a magnetically operated matrix printer a circuit makes a decision when a magnet is actuated. The decision is whether or not the relevant magnet has already been actuated during the printing of the previous column of the matrix character being printed. When it has not been actuated, it is actuated with a larger quantity of energy (longer pulse). Thus the operation of the printer is in "resonance" with the mechanical movements of the magnet armature.

Abstract: In a serial electrostatic printer, the developing device has a magnetic brush feeding toner to the record carrier, divided into a large number of magnetic regions. The magnetic region trailing the printing location is activated after printing.